Table 4.
Characteristics of Myositis Prevalent Patients (2004–2008)
| |
Commercial and Medicare patients |
Medicaid patients |
||
|---|---|---|---|---|
| n | % | n | % | |
|
Myositis (Overall)1 |
5,941 |
100.0% |
1,214 |
100.0% |
| Dermatomyositis |
2,361 |
39.7% |
440 |
36.2% |
| Polymyositis |
3,443 |
58.0 |
771 |
63.5 |
| Interstitial myositis |
585 |
9.8% |
115 |
9.5% |
|
Year2 | ||||
| 2004 |
1,865 |
31.4% |
684 |
56.3% |
| 2005 |
2,197 |
37.0% |
574 |
47.3% |
| 2006 |
2,242 |
37.7% |
355 |
29.2% |
| 2007 |
2,562 |
43.1% |
335 |
27.6% |
| 2008 |
2,605 |
43.8% |
306 |
25.2% |
|
Age | ||||
| 18-24 |
249 |
4.2% |
104 |
8.6% |
| 25-34 |
334 |
5.6% |
145 |
11.9% |
| 35-44 |
774 |
13.0% |
254 |
20.9% |
| 45-54 |
1,403 |
23.6% |
264 |
21.7% |
| 55-64 |
1,773 |
29.8% |
248 |
20.4% |
| 65-74 |
810 |
13.6% |
118 |
9.7% |
| 75+ |
598 |
10.1% |
81 |
6.7% |
|
Gender | ||||
| Female |
4,029 |
67.8% |
928 |
76.4% |
| Male |
1,912 |
32.2% |
286 |
23.6% |
|
Race/Ethnicity (N, %) | ||||
| Caucasian |
…. |
…. |
440 |
36.2% |
| African American |
…. |
…. |
540 |
44.5% |
| Hispanic |
…. |
…. |
81 |
6.7% |
| Other/Unknown |
…. |
…. |
15 |
1.2% |
|
Region | ||||
| Northeast |
652 |
11.0% |
…. |
…. |
| North Central |
1,668 |
28.1% |
…. |
…. |
| South |
2,416 |
40.7% |
…. |
…. |
| West |
1,167 |
19.6% |
…. |
…. |
| Unknown |
38 |
0.6 % |
…. |
…. |
|
Urbanization | ||||
| Urban |
4,991 |
84.0% |
…. |
…. |
| Rural |
917 |
15.4% |
…. |
…. |
| Unknown |
33 |
0.6% |
…. |
…. |
|
Medicare |
1,417 |
23.9% |
460 |
37.9 % |
|
Fee-for-service (N, %) | ||||
| Fee-for-service |
3,639 |
61.3 % |
850 |
70.0% |
| Not fee-for-service |
2,302 |
38.7% |
363 |
29.9% |
| Unknown |
0 |
0% |
1 |
0.1% |
|
Clinical Conditions | ||||
| Rheumatoid Arthritis |
349 |
5.9% |
114 |
9.4% |
| Systemic lupus erythematosus |
317 |
5.3% |
111 |
9.1% |
| Systemic sclerosis |
93 |
1.6% |
34 |
2.8% |
| Cushing syndrome |
6 |
0.1% |
7 |
0.6% |
| Addison's disease |
16 |
0.3% |
7 |
0.6% |
| Other Inflammatory Arthritis/Arthropathies |
983 |
16.5% |
309 |
25.5% |
| Back problems |
1074 |
18.1% |
249 |
20.5% |
| Dysphagia |
213 |
3.6% |
67 |
5.5% |
| Hypertension |
1578 |
26.6% |
494 |
40.7% |
| Diabetes |
764 |
12.9% |
299 |
24.6% |
| Depression |
299 |
5.0% |
191 |
15.7% |
| Malignancy |
467 |
7.9% |
94 |
7.7% |
|
Medications on or 365 days after index date | ||||
| Systemic corticosteriods |
4,507 |
75.9% |
881 |
72.6% |
| Topical corticosteroids |
4,155 |
69.9% |
841 |
69.3% |
| Methotrexate |
1,887 |
31.8% |
281 |
23.1% |
| Azathioprine |
993 |
16.7% |
234 |
19.3% |
| Hydroxychloroquine |
926 |
15.6% |
142 |
11.7% |
| Intravenous immunoglobulin |
79 |
1.3% |
20 |
1.6% |
| Cyclosporine |
202 |
3.4% |
17 |
1.4% |
| Mycophenolate mofetil |
402 |
6.8% |
61 |
5.0% |
| Leflunomide |
73 |
1.2% |
15 |
1.2% |
| Thalidomide |
4 |
0.1 % |
0 |
0.0 % |
| Cyclophosphamide |
83 |
1.4% |
25 |
2.1% |
| Tacrolimus |
158 |
2.7% |
11 |
0.9% |
| Rituximab | 48 | 0.8% | 4 | 0.3% |
1Myositis subgroups were not mutually exclusive, and patients could be assigned to more than one subgroup.
2Yearly counts reflect number of prevalent patients identified in each year and are not mutually exclusive.